These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 699334)

  • 21. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of 5-S-cysteinyldopa by high performance liquid chromatography in biopsies from patients with dysplastic melanocytic nevi.
    Halldin MM; Cook WS; Kawashima T; Crutcher WA; Fukuyama K
    Cancer Res; 1987 Jan; 47(2):636-8. PubMed ID: 3098416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
    Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
    Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
    Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-S-cysteinyldopa as a substrate for tyrosinase.
    Hansson C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1980; 60(5):399-402. PubMed ID: 6162310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved solid-phase extraction and liquid chromatography with electrochemical detection of urinary catecholamines and 5-S-L-cysteinyl-L-dopa.
    Huang TH; Wall J; Kabra P
    J Chromatogr; 1988 Oct; 452():409-18. PubMed ID: 3149647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
    Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved HPLC determination of 5-S-cysteinyldopa in serum.
    Wakamatsu K; Ito S
    Clin Chem; 1994 Mar; 40(3):495-6. PubMed ID: 8131290
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis of 5-S-L-cysteinyl-glycine-L-dopa, a natural substrate for serum and melanocyte dipeptidase.
    Kågedal B; Gawelin AL; Pettersson A
    Anal Biochem; 1987 Aug; 165(1):167-74. PubMed ID: 3120620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection.
    Hansson C; Agrup G; Rorsman H; Rosengren AM; Rosengren E; Edholm LE
    J Chromatogr; 1979 Jan; 162(1):7-22. PubMed ID: 33194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diastereomers of 5-S-cysteinyldopa.
    Agrup G; Edholm LE; Rorsman H; Rosengren E
    Acta Derm Venereol; 1983; 63(1):59-61. PubMed ID: 6191491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
    Meyer T; Hauschild A; Kromminga A; Hartleb J; Arndt R; Christophers E; Stockfleth E
    Melanoma Res; 2002 Oct; 12(5):471-7. PubMed ID: 12394189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up.
    Martin GB; Chiap P; Paquet P; Pierard G; de Tullio P; Martin Y; Rozet E; Hubert P; Crommen J; Fillet M
    J Chromatogr A; 2007 Jul; 1156(1-2):141-8. PubMed ID: 17229429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.
    Goto H; Usui M; Wakamatsu K; Ito S
    Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of DOPA-loading on glutathione-dependent 5-S-cysteinyldopa genesis in melanoma cells in vitro.
    Mojamdar M; Ichihashi M; Mishima Y
    J Invest Dermatol; 1982 Mar; 78(3):224-6. PubMed ID: 6799583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels.
    Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T
    Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaquinone addition products in cultured human melanoma cells.
    Carstam R; Hansson C; Lindbladh C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1987; 67(2):100-5. PubMed ID: 2438872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V; Paul E
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-S-cysteinyldopa and pigment response to UVA light.
    Tegner E; Rorsman H; Rosengren E
    Acta Derm Venereol; 1983; 63(1):21-5. PubMed ID: 6191484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.